Literature DB >> 2966981

Safety and tolerance of trimetrexate: results of a phase II multicenter study in patients with metastatic cancer refractory to conventional therapy or for which no conventional therapy exists.

J A Stewart1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2966981

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

1.  Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.

Authors:  F V Fossella; R J Winn; P Y Holoye; B Hallinan; M N Raber; K Hoelzer; J A Young; J Readling; B Bowers; W K Hong
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

2.  Trimetrexate in locally advanced or metastatic adenocarcinoma of the pancreas. A phase II study of the Northern California Oncology Group.

Authors:  R W Carlson; J H Doroshow; O O Odujinrin; M S Flam; M Malec; K R Lamborn
Journal:  Invest New Drugs       Date:  1990-11       Impact factor: 3.850

3.  Hypersensitivity reactions to trimetrexate.

Authors:  J L Grem; S A King; M E Costanza; T D Brown
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

Review 4.  Clinical pharmacokinetics and pharmacology of trimetrexate.

Authors:  J L Marshall; R J DeLap
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.